A New Era in Oncology

Harnessing the Power of Phosphoramidate Chemistry

Unlocking the Potential of Immunotherapy

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines.

NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.

Mission Statement

“To significantly improve the survival outcomes for patients and pioneer a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Discover more

Hugh Griffith CEO

Latest News

July 2025

NuCana Announces Plan to Implement ADS Ratio Change

June 2025

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

May 2025

NuCana Prices $7 Million Registered Direct Offering

More news

Contact NuCana

Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK

info@nucana.com

+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466

info@nucana.com

+1 617 663 5708

* These fields are required.